

LITERATURA

1. Castellano JM, Pocock SJ, Bhatt DL, et al. SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. *N Engl J Med.* 2022 Sep 15;387(11):967-977.
2. Mackenzie IS, Rogers A, Poulter NR, et al. *Lancet.* 2022 Oct 22;400(10361):1417-1425.
3. Tita AT, Szychowski JM, Boggess K, et al. Chronic Hypertension and Pregnancy (CHAP) Trial Consortium. Treatment for Mild Chronic Hypertension during Pregnancy. *N Engl J Med.* 2022 May 12;386(19):1781-1792.
4. Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. *Eur Heart J.* 2022 Oct 14;43(39):3826-3924.
5. Kjaergaard J, Møller JE, Schmidt H, et al. Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest. *N Engl J Med.* 2022 Oct 20;387(16):1456-1466.
6. Schmidt H, Kjaergaard J, Hassager C, et al. Oxygen Targets in Comatose Survivors of Cardiac Arrest. *N Engl J Med.* 2022 Oct 20;387(16):1467-1476.
7. Solomon SD, McMurray JJV, Claggett B, et al. DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. *N Engl J Med.* 2022 Sep 22;387(12):1089-1098.
8. Ezekowitz JA, Colin-Ramirez E, Ross H, et al. SODIUM-HF Investigators. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. *Lancet.* 2022 Apr 9;399(10333):1391-1400. Erratum in: *Lancet.* 2022 Oct 8;400(10359):1194.
9. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. *Lancet.* 2022 Dec 3;400(10367):1938-1952.
10. Ishani A, Cushman WC, Leatherman SM, et al. Diuretic Comparison Project Writing Group. Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. *N Engl J Med.* 2022 Dec 29;387(26):2401-2410.

ON-LINE KURZ

On-line kurz Kardiovaskulární onemocnění

2

PŘEDNÁŠKY

- **Léčba hypertenze v roce 2022? Cílem je snížit riziko kardiovaskulární příhody!** – MUDr. Petra Vysočanová
- **Dušnost** – MUDr. Marek Šramko, Ph.D.
- **Bolest na hrudi** – doc. MUDr. Jiří Kettner, CSc.
- **Palpitace** – prof. MUDr. Josef Kautzner, CSc., FESC
- **Synkopy** – MUDr. Jana Hašková

POČET
KREDITŮ **2**Registrace
ZDARMA

TERMÍN

květen 2022
až květen 2023dostupný na
online.solen.cz

ODBORNÝ GARANT

MUDr. Petra Vysočanová
Fakultní nemocnice Brno-Bohunice,
Interní kardiologická klinika

PARTNER

SERVIER
moved by you

KONTAKT: Mgr. Vendula Pávková
+420 777 714 679 | pavkova@solen.cz